Pairidex Appoints Oncology Diagnostics Commercial Leader Matt Sargent to Board of Directors
ST. LOUIS, MO – September 30, 2026 – Pairidex, a developer of personalized monitoring assays for fusion-driven blood cancers, today announced the appointment of Matt Sargent to its Board of Directors. Sargent brings more than 20 years of experience leading commercial teams in oncology diagnostics and will be a key advisor as Pairidex advances the commercialization of FusionMRD™, its ultra-sensitive...
Haematologica Publication Highlights Earlier Leukemia Relapse Detection With Technology Behind FusionMRD™Washington University School of Medicine study used digital PCR technology exclusively licensed to Pairidex, now available as the FusionMRD™ test
Pairidex Inc., a leader in personalized disease monitoring for fusion-driven blood cancers, today announced a peer-reviewed study in Haematologica on personalized, blood-based digital PCR testing in patients with KMT2A-rearranged acute leukemia. In all cases where patients relapsed and samples were banked during treatment, the test detected disease weeks to months before standard-of-care testing. The study was led by Andrew L....
Pairidex Appoints Allyson Mayer, PhD, as Chief Operating Officer
Pairidex, an emerging leader in MRD testing for hematologic malignancies, today announced the appointment of Allyson Mayer, PhD, as Chief Operating Officer. Mayer joined Pairidex July 20 to support the company’s commercial launch of FusionMRD, a laboratory-developed test (LDT) for personalized monitoring of fusion-driven blood cancers. As Chief Operating Officer, Mayer will oversee Pairidex’s operations and support the company’s continued...
Pairidex Closes Over-Subscribed Seed Round to Support the Launch of New Highly Sensitive MRD Test for LeukemiaThe financing brings in $4.89M in new capital to accelerate the commercial launch of FusionMRD™
ST. LOUIS, MO, UNITED STATES -- Pairidex, a precision diagnostics company advancing personalized molecular testing for hematologic malignancies, today announced the successful close of its oversubscribed Seed financing round. The financing brings in $4.89M in new capital to accelerate the commercial launch of FusionMRD™, the company's personalized, RNA-based laboratory developed test (LDT) for monitoring measurable residual disease (MRD) in fusion-driven...
Cancer MRD Testing Startup Pairidex Raises $4.9M in Seed Financing
NEW YORK – Cancer precision diagnostics startup Pairidex on Monday announced the close of a $4.89 million seed financing round. The St. Louis, Missouri-based company did not name the investor but said that it is a large, publicly held strategic company, and that the round was oversubscribed. The firm plans to use the funding to speed up commercialization of FusionMRD,...
Pairidex Secures Lead Investment from BioGenerator Ventures for the Launch of New Highly Sensitive MRD Test for LeukemiaReducing Uncertainty in the Care and Treatment of Blood Cancer
ST. LOUIS, MO, UNITED STATES, February 23, 2026 /EINPresswire.com/ -- Pairidex, an emerging leader in leukemia detection, today announced a lead investment from BioGenerator Ventures that will enable the launch of FusionMRD™, a new personalized, RNA-based assay for the monitoring of measurable residual disease (MRD) in fusion-driven hematological malignancies. FusionMRD™ is commercially available as a laboratory developed test (LDT) for...
Pairidex Featured in St. Louis Business Journal
PAIRIDEX Headquarters: St. Louis (BioGenerator Labs in the Cortex district) What it does: Pairidex is developing a novel droplet digital PCR platform for more accurate, personalized monitoring of blood cancer. The latest: Pairidex established operations just over one year ago. Since then, Pairidex has closed an oversubscribed pre-seed round, licensed the necessary IP from WashU, established a CLIA-certified laboratory, and completed its first commercial sale. Why you should watch it: Our mission is to...
We are thrilled to announce the appointment of Paul Kortschak as the new Chief Executive Officer of Pairidex
Paul brings to Pairidex over 20 years of executive leadership experience across the biotech and clinical industries, with a proven track record of driving innovation, scaling organizations, and building high-performing teams. Most recently, he served as CEO at NX Prenatal. Pairidex continues to grow and evolve in developing droplet digital PCR assays designed to enable accurate detection of gene fusions...
Pairidex Welcomes Eric Green, M.D., Ph.D. as an Advisor
Pairidex welcomes Eric Green, M.D., Ph.D., former director of the National Human Genome Research Institute (NHGRI) at the U.S. National Institutes of Health (NIH) from 2009 to 2025 as an Advisor. Dr. Green guided work aimed at improving our understanding of human genetics and using those findings to help develop treatments for genetic diseases. Dr. Green will provide valuable input as...
Unlocking Potential: How Science Coach and BioSTL Are Shaping the Future of STEM EducationFrom Small-Town Roots to Bioscience Innovation
From Small-Town Roots to Bioscience Innovation When all the pieces fall into place, miraculous things happen. Hannah Davis is living proof. At 23, she’s a promising scientist and Research Associate at Pairidex, Inc., a company focused on pioneering blood cancer detection methods—potentially life-saving innovations for leukemia patients. Her journey, from a small-town high school to cutting-edge biomedical research, represents the full realization of BioSTL’s vision to change the world...
Innovators Hour: Interview with Andrew Young & Allyson Mayer of Pairidex
Jim McCarter, Senior Managing Director of BioGenerator Ventures, sits down with Andrew Young, MD, PhD, of Pairidex and WashU, and Allyson Mayer, PhD, of Pairidex and BioGenerator Ventures. Pairidex is the developer of a droplet digital PCR assay designed to enable accurate detection of gene fusions in blood cancer. Innovators Hour, hosted by BioGenerator, the start-up arm of BioSTL, spotlights...
Pairidex announces new clinical test to monitor leukemia patient therapeutic responsePairidex today announced the launch of FusionMRD™, for the monitoring of measurable residual disease (MRD) in fusion-driven hematological malignancies.
ST. LOUIS, MO, UNITED STATES, February 23, 2026 /EINPresswire.com/ -- Pairidex, an emerging leader in leukemia detection, today announced the launch of FusionMRD™, a new personalized, RNA-based assay for the monitoring of measurable residual disease (MRD) in fusion-driven hematological malignancies that is now available as a laboratory-developed test (LDT) in the United States. FusionMRD™ is commercially available for personalized gene...
Technical Advance: Droplet Digital PCR for Oncogenic KMT2A Fusion
Acute myeloid leukemia (AML) is an aggressive blood cancer diagnosed in approximately 120,000 individuals worldwide each year. During treatment for AML, detecting residual disease is essential for prognostication and treatment decision-making. Currently, methods for detecting residual AML are limited to identifying approximately 1:100 to 1:1000 leukemic cells (morphology and DNA sequencing) or are difficult to implement...
Connect with us
Discover how our innovative solutions can transform your approach to cancer detection and monitoring. We’d love to show you what we can do.